AMRI Announces $10 Million Share Repurchase Program: AMRI & PWRM

June 21, 2010 - PRLog -- Albany Molecular Research Inc. (NasdaqGS: AMRI)

Last: $5.77

Change: +$0.13 (+3.03%)

Albany Molecular Research Inc. announced today that its board of directors has approved a new share repurchase program of up to $10 million.  Under the program, the company is authorized to repurchase outstanding shares of its Common Stock in the open market or in private transactions.  Shares may be repurchased from time to time and in such amounts as market conditions warrant, subject to price ranges set by management and regulatory considerations.

"This program underscores our confidence in AMRI's business and our commitment to returning value to our shareholders," said AMRI Chairman and CEO Thomas E. D'Ambra, Ph.D. "We believe that current share price levels represent an attractive investment, particularly in view of the many longer term strategic initiatives AMRI has undertaken over the past six months.  The size of the program announced today still positions the company with the financial resources and flexibility to evaluate further growth opportunities as they arise."

About:

Founded in 1991, Albany Molecular Research Inc. provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the United States , Europe, and Asia , AMRI provides customers with a wide range of services, technologies and cost models.


Visit: http://www.amriglobal.com/index.cfm

______________________________________



POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)

Last:$0.0386

PWRM is now available for $0.0386 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover:

Processes - The manner in which the discoveries are made and tests developed
Discoveries - Protein disease footprints,
Products - Early detection tests, Biomarkers, and Drug Targets

The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance:

The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance as depicted below:

Two of Power3 Medical Areas of Research

Breast Cancer

Power3’s early indication breast cancer NAF protein footprint test
More than 120 identified NAF protein biomarkers and drug targets for early indication and treatment of breast cancer
NAF footprints for individualized therapy



Neurodegenerative Diseases - ALS (Lou Gehrig’s Disease), Alzheimer’s Disease, Parkinson’s Disease, Other Neurological Disorders

Power3’s blood serum test for distinguishing between the neurodegenerative diseases
Blood serum biomarkers and drug targets for neurodegenerative disease



Resistance to Chemotherapy

Power3’s test for prediction of response to drug therapy in cancer
Biomarkers and drug targets for treatment and monitoring of drug resistance





Continue your research at www.power3medical.com

*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.StockHotTips.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEpicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

*******************************************